ClinicalTrials.gg
CompletedNCT04365387Updated Jun 1, 2026Results posted

A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab

A Phase 2 interventional study of Nemolizumab and Placebo in Dermatitis, Atopic, sponsored by Galderma R&D. Completed at 64 sites in United States. Open to participants aged 12 Years to 54 Years. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
242
Allocation
Randomized
Ages
12 Years to 54 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing nemolizumab in Dermatitis, Atopic — 3 open to participants now, 3 under way, 1 of them phase 3. nemolizumab · Dermatitis, Atopic.

Enrollment
5th of 14
242 · median 209
Started
2020
the only one that year
Phase 2
7 of 14
1 open now
Registered
7th of 14
by date
Lead sponsor
12 of 14
Galderma R&D

Among the 14 studies testing nemolizumab in Dermatitis, Atopic, this one is the 5th largest by enrollment, is the only one that started in 2020, is one of 7 in phase 2, and was the 7th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

3 of the 14 studies testing nemolizumab in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About nemolizumab

nemolizumab: first FDA approval 2024 (NEMLUVIO), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years to 54 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing nemolizumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The purpose of this study is to assess the effect of nemolizumab (CD14152) on humoral immune responses to tetanus and meningococcal vaccination in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD).

Read the detailed description

This is a randomized, double-blind, placebo-controlled, multi-center, parallel-group study in adult and adolescent participants (≥ 12 to 54 years) with moderate-to-severe AD. Eligible participants must have a documented history of inadequate response to topical AD medication(s). Approximately 200 participants were randomized 1:1 to receive either 30 mg nemolizumab (with a 60 mg loading dose) or placebo, stratified by baseline disease severity Investigator Global Assessment (IGA) (IGA = 3, moderate; IGA = 4, severe). The study consisted of a 2- to 4-week screening period, a 16-week treatment period, and an 8-week follow-up period (12 weeks after the last study drug injection).

03

Conditions studied

  • Dermatitis, Atopic

Keywords

  • Eczema
  • AD
  • Vaccine
  • Nemolizumab
  • Pruritis
  • Itchy
04

Who can participate

Ages eligible
12 Years to 54 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic AD for at least 2 years
  • EASI score >= 16
  • IGA score >= 3
  • AD involvement >= 10% of BSA
  • Peak (maximum) pruritus NRS score of at least 4.0

Exclusion criteria

Exclusion Criteria:

  • Body weight \< 30 kilogram (kg)
  • History of (including anaphylaxis) to an immunoglobulin product (plasma-derived or recombinant, eg, monoclonal antibody) or to any of the study drug
  • History of severe allergic reaction to either vaccine or to vaccine components including alum, thimerosal, phenol
  • Participants for whom administration of the meningococcal vaccine provided in this study is or medically inadvisable
  • Participants for whom administration of the tetanus, diphtheria, and pertussis vaccine provided in this study is contraindicated or medically inadvisable
  • Receipt of any vaccine (except inactivated influenza vaccine) within 12 weeks prior to screening, any meningococcal vaccine within 1 year prior to screening, or any tetanus-, diphtheria-, or pertussis-containing vaccine within 5 years prior to screening
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
242 participants (actual)

Study arms

  • Experimental
    Nemolizumab

    Participants received a loading dose of nemolizumab (60 milligram \[mg\]) via 2 subcutaneous (SC) injections at baseline. Nemolizumab (30 mg) was administered via a single subcutaneous injection every 4 weeks (Q4W) at Weeks 4, 8, and 12.

    Drug: Nemolizumab

  • Placebo comparator
    Placebo

    Participants received a placebo via 2 SC injections at baseline. Placebo was administered via a single subcutaneous injection Q4W at Weeks 4, 8, and 12.

    Drug: Placebo

Interventions

  • Nemolizumab was administered by 2 SC injections as 60-mg loading dose at baseline and a single 30-mg dose at Weeks 4, 8, and 12.

  • DrugPlacebo

    Placebo was administered by 2 SC injections at baseline and a single dose at Weeks 4, 8, and 12.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Positive Serum Immunoglobulin G (IgG) Response (>= 4-Fold Increase or >= 0.2 IU/mL in Anti-Tetanus IgG Concentrations) to Tetanus Toxoid at Week 16 (4 Weeks Post-vaccination)

    Percentage of participants with a positive serum IgG response to tetanus toxoid, defined as greater than or equal to (\>=) 4-fold increase in anti-tetanus IgG concentrations from baseline in participants with pre-vaccination anti-tetanus IgG concentrations \>= 0.1 international unit per milliliter (IU/mL); or \>= 0.2 IU/mL anti-tetanus IgG concentrations in participants with pre-vaccination antitetanus IgG concentrations less than (\<) 0.1 IU/mL, at Week 16 (4 weeks post-vaccination) were reported.

    Time frame: At Week 16 (4 weeks post-vaccination)

Secondary outcomes

  1. Percentage of Participants With a Positive Serum IgG Response (>=2-Fold Increase or >= 0.2 IU/mL in Anti-tetanus IgG Concentrations) to Tetanus Toxoid at Week 16 (4 Weeks Post-vaccination)

    Percentage of participants with a positive serum IgG response to tetanus toxoid, defined as \>= 2-fold increase in anti-tetanus IgG concentrations from baseline in participants with pre-vaccination anti-tetanus IgG concentrations \>= 0.1 IU/mL; or \>= 0.2 IU/mL anti-tetanus IgG concentrations in participants with pre-vaccination Anti tetanus IgG concentrations \< 0.1 IU/mL, at Week 16 (4 weeks post-vaccination) were reported.

    Time frame: At Week 16 (4 weeks post-vaccination)

  2. Percentage of Participants With Serum Anti-tetanus IgG Concentrations of >= 0.1 IU/mL at Week 16

    Percentage of participants with serum anti-tetanus IgG concentrations of \>= 0.1 IU/mL at Week 16 were reported. The detection and characterization of antibodies to tetanus toxoid was performed using a validated immunoassay.

    Time frame: At Week 16

  3. Percentage of Participants With Serum Anti-tetanus IgG Concentrations of >= 1.0 IU/mL at Week 16

    Percentage of participants with serum anti-tetanus IgG concentrations of \>= 1.0 IU/mL at Week 16 were reported. The detection and characterization of antibodies to tetanus toxoid was performed using a validated immunoassay.

    Time frame: At Week 16

  4. Percentage of Participants With a Positive Serum Bactericidal Antibody (SBA) Response to Meningococcal Serogroup C (MenC) Polysaccharide at Week 16

    Percentage of participants with a positive SBA response to meningococcal serogroup C polysaccharide, defined as \>= 4-fold increase in SBA reciprocal titer from baseline (using non-imputed values), at Week 16 (4 weeks postvaccination) were reported.

    Time frame: At Week 16

  5. Percentage of Participants With a Positive SBA Response (Defined as SBA Reciprocal Titer ≥8) to MenC Polysaccharide at Week 16

    Percentage of participants with a positive SBA response to MenC polysaccharide, defined as SBA reciprocal titer \>= 8, at Week 16 were reported. Immune response to meningococcal vaccination was determined by measuring functional antibody responses using an SBA assay.

    Time frame: At Week 16

07

Results

Posted Jun 5, 2025

Participant flow

The study was conducted at 42 sites in United states from 05 Mar 2020 to 07 Jul 2023.

Participant flow — Overall Study
MilestoneNemolizumabPlacebo
Started123119
Modified intent to treat (mitt) population8078
Safety population119115
Completed9093
Not completed3326
Withdrew: Adverse event42
Withdrew: Participants request1414
Withdrew: Lost to follow-up85
Withdrew: Protocol deviation34
Withdrew: Participant compliance with visit schedule10
Withdrew: Participant incarcerated10
Withdrew: Participant moved out of town (relocated)01
Withdrew: Participant pef not eligible per sponsor10
Withdrew: Due to working hours, could not return to other visits10

Outcome measures

PrimaryPercentage of Participants With a Positive Serum Immunoglobulin G (IgG) Response (>= 4-Fold Increase or >= 0.2 IU/mL in Anti-Tetanus IgG Concentrations) to Tetanus Toxoid at Week 16 (4 Weeks Post-vaccination)

Percentage of participants with a positive serum IgG response to tetanus toxoid, defined as greater than or equal to (\>=) 4-fold increase in anti-tetanus IgG concentrations from baseline in participants with pre-vaccination anti-tetanus IgG concentrations \>= 0.1 international unit per milliliter (IU/mL); or \>= 0.2 IU/mL anti-tetanus IgG concentrations in participants with pre-vaccination antitetanus IgG concentrations less than (\<) 0.1 IU/mL, at Week 16 (4 weeks post-vaccination) were reported.

Time frame:
At Week 16 (4 weeks post-vaccination)
Reported as:
Number · Percentage of Participants
Percentage of Participants With a Positive Serum Immunoglobulin G (IgG) Response (>= 4-Fold Increase or >= 0.2 IU/mL in Anti-Tetanus IgG Concentrations) to Tetanus Toxoid at Week 16 (4 Weeks Post-vaccination)
Percentage of ParticipantsNemolizumabPlacebo
Percentage of Participants With a Positive Serum Immunoglobulin G (IgG) Response (>= 4-Fold Increase or >= 0.2 IU/mL in Anti-Tetanus IgG Concentrations) to Tetanus Toxoid at Week 16 (4 Weeks Post-vaccination)67.565.4
Statistical analysis
  • Nemolizumab vs Placebo · Cochran-mantel-haenszel: 2.1 · 90% CI -10.3 to 14.5Risk Difference (90% CI) were estimated using weighted average of stratum-specific proportion using Cochran-Mantel-Haenszel (CMH).
SecondaryPercentage of Participants With a Positive Serum IgG Response (>=2-Fold Increase or >= 0.2 IU/mL in Anti-tetanus IgG Concentrations) to Tetanus Toxoid at Week 16 (4 Weeks Post-vaccination)

Percentage of participants with a positive serum IgG response to tetanus toxoid, defined as \>= 2-fold increase in anti-tetanus IgG concentrations from baseline in participants with pre-vaccination anti-tetanus IgG concentrations \>= 0.1 IU/mL; or \>= 0.2 IU/mL anti-tetanus IgG concentrations in participants with pre-vaccination Anti tetanus IgG concentrations \< 0.1 IU/mL, at Week 16 (4 weeks post-vaccination) were reported.

Time frame:
At Week 16 (4 weeks post-vaccination)
Reported as:
Number · Percentage of Participants
Percentage of Participants With a Positive Serum IgG Response (>=2-Fold Increase or >= 0.2 IU/mL in Anti-tetanus IgG Concentrations) to Tetanus Toxoid at Week 16 (4 Weeks Post-vaccination)
Percentage of ParticipantsNemolizumabPlacebo
Percentage of Participants With a Positive Serum IgG Response (>=2-Fold Increase or >= 0.2 IU/mL in Anti-tetanus IgG Concentrations) to Tetanus Toxoid at Week 16 (4 Weeks Post-vaccination)78.883.3
Statistical analysis
  • Nemolizumab vs Placebo · Cochran-mantel-haenszel: -4.6 · 90% CI -14.9 to 5.7Risk Difference (90% CI) were estimated using weighted average of stratum-specific proportion using CMH.
SecondaryPercentage of Participants With Serum Anti-tetanus IgG Concentrations of >= 0.1 IU/mL at Week 16

Percentage of participants with serum anti-tetanus IgG concentrations of \>= 0.1 IU/mL at Week 16 were reported. The detection and characterization of antibodies to tetanus toxoid was performed using a validated immunoassay.

Time frame:
At Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants With Serum Anti-tetanus IgG Concentrations of >= 0.1 IU/mL at Week 16
Percentage of ParticipantsNemolizumabPlacebo
Percentage of Participants With Serum Anti-tetanus IgG Concentrations of >= 0.1 IU/mL at Week 16100100
SecondaryPercentage of Participants With Serum Anti-tetanus IgG Concentrations of >= 1.0 IU/mL at Week 16

Percentage of participants with serum anti-tetanus IgG concentrations of \>= 1.0 IU/mL at Week 16 were reported. The detection and characterization of antibodies to tetanus toxoid was performed using a validated immunoassay.

Time frame:
At Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants With Serum Anti-tetanus IgG Concentrations of >= 1.0 IU/mL at Week 16
Percentage of ParticipantsNemolizumabPlacebo
Percentage of Participants With Serum Anti-tetanus IgG Concentrations of >= 1.0 IU/mL at Week 1697.596.2
Statistical analysis
  • Nemolizumab vs Placebo · Cochran-mantel-haenszel: 1.4 · 90% CI -3.2 to 5.9Risk Difference (90% CI) were estimated using weighted average of stratum-specific proportion using CMH.
SecondaryPercentage of Participants With a Positive Serum Bactericidal Antibody (SBA) Response to Meningococcal Serogroup C (MenC) Polysaccharide at Week 16

Percentage of participants with a positive SBA response to meningococcal serogroup C polysaccharide, defined as \>= 4-fold increase in SBA reciprocal titer from baseline (using non-imputed values), at Week 16 (4 weeks postvaccination) were reported.

Time frame:
At Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants With a Positive Serum Bactericidal Antibody (SBA) Response to Meningococcal Serogroup C (MenC) Polysaccharide at Week 16
Percentage of ParticipantsNemolizumabPlacebo
Percentage of Participants With a Positive Serum Bactericidal Antibody (SBA) Response to Meningococcal Serogroup C (MenC) Polysaccharide at Week 1677.063.6
Statistical analysis
  • Nemolizumab vs Placebo · Cochran-mantel-haenszel: 13.3 · 90% CI 0.1 to 26.4Risk Difference (90% CI) were estimated using weighted average of stratum-specific proportion using CMH for non-Imputed values
SecondaryPercentage of Participants With a Positive SBA Response (Defined as SBA Reciprocal Titer ≥8) to MenC Polysaccharide at Week 16

Percentage of participants with a positive SBA response to MenC polysaccharide, defined as SBA reciprocal titer \>= 8, at Week 16 were reported. Immune response to meningococcal vaccination was determined by measuring functional antibody responses using an SBA assay.

Time frame:
At Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants With a Positive SBA Response (Defined as SBA Reciprocal Titer ≥8) to MenC Polysaccharide at Week 16
Percentage of ParticipantsNemolizumabPlacebo
Percentage of Participants With a Positive SBA Response (Defined as SBA Reciprocal Titer ≥8) to MenC Polysaccharide at Week 1683.381.9
Statistical analysis
  • Nemolizumab vs Placebo · Cochran-mantel-haenszel: 1.3 · 90% CI -9.3 to 11.9Risk Difference (90% CI) were estimated using weighted average of stratum-specific proportion using CMH.

Adverse events

Collected over From Day 1 up to end of study (Week 24). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nemolizumab0/119 (0%)0/119 (0%)44/119 (37%)
Placebo0/115 (0%)1/115 (0.9%)38/115 (33%)
Most frequent serious events
Most frequent serious events
EventNemolizumabPlacebo
AsthmaRespiratory, thoracic and mediastinal disorders0/1191/115
Most frequent other events
Showing 10 of 78
Most frequent other events
EventNemolizumabPlacebo
Dermatitis atopicSkin and subcutaneous tissue disorders13/1196/115
HeadacheNervous system disorders6/1191/115
AsthmaRespiratory, thoracic and mediastinal disorders2/1194/115
COVID-19Infections and infestations4/1192/115
HyperlipidaemiaMetabolism and nutrition disorders3/1191/115
ProteinuriaRenal and urinary disorders3/1190/115
Gamma-glutamyltransferase increasedInvestigations0/1192/115
ArthralgiaMusculoskeletal and connective tissue disorders2/1192/115
DiarrhoeaGastrointestinal disorders1/1192/115
Alanine aminotransferase increasedInvestigations2/1191/115

Baseline characteristics

Intent-to-Treat Population (ITT) population consisted of all randomized participants.

Age, Continuous
Age, Continuous(Years)NemolizumabPlaceboTotal
Mean35.2 ± 11.6232.1 ± 12.0033.6 ± 11.89
Sex: Female, Male
Sex: Female, Male(Participants)NemolizumabPlaceboTotal
Female7869147
Male455095
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)NemolizumabPlaceboTotal
Hispanic or Latino434588
Not Hispanic or Latino7973152
Unknown or Not Reported112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)NemolizumabPlaceboTotal
American Indian or Alaska Native022
Asian131932
Native Hawaiian or Other Pacific Islander123
Black or African American353166
White7062132
More than one race123
Unknown or Not Reported314
08

Study locations

64 sites
  • Galderma Investigational Site (Site#9922)
    Phoenix, Arizona 85018, United States
  • Galderma Investigational Site (Site#8873)
    Scottsdale, Arizona 85260, United States
  • Galderma Investigational Site (Site#8447)
    Fort Smith, Arkansas 72916, United States
  • Galderma Investigational Site (Site#8831)
    Anaheim, California 92801, United States
  • Galderma Investigational Site (Site#8854)
    Canoga Park, California 91303, United States
  • Galderma Investigational Site (Site#8578)
    Cerritos, California 90703, United States
  • Galderma Investigational Site (Site#8791)
    Fresno, California 93720, United States
  • Galderma Investigational Site (Site#8845)
    Huntington Beach, California 92647, United States
  • Galderma Investigational Site (Site#8833)
    Inglewood, California 90301, United States
  • Galderma Investigational Site 2 (Site#8833)
    Inglewood, California 90301, United States
  • Galderma Investigational Site (Site#8858)
    Long Beach, California 90806, United States
  • Galderma Investigational Site (Site#8130)
    Los Angeles, California 90045, United States
  • Galderma Investigational Site (Site#8813)
    Los Angeles, California 90057, United States
  • Galderma Investigational Site (Site#8837)
    Pomona, California 91767, United States
  • Galderma Investigational Site (SIte#8870)
    Boca Raton, Florida 33433, United States
  • Galderma Investigational Site (Site#8786)
    Clearwater, Florida 33765, United States
  • Galderma Investigational Site (Site#8792)
    Doral, Florida 33122, United States
  • Galderma Investigational Site (Site#8391)
    Hialeah, Florida 33013, United States
  • Galderma Investigational Site (Site#8836)
    Jacksonville, Florida 32256, United States
  • Galderma Investigational Site (Site#8850)
    Margate, Florida 33063, United States
  • Galderma Investigational Site (Site#8851)
    Miami, Florida 33135, United States
  • Galderma Investigational Site (Site#9921)
    Miami Lakes, Florida 33014, United States
  • Galderma Investigational Site (Site#8840)
    Ocoee, Florida 34761, United States
  • Galderma Investigational Site (Site#8788)
    Orlando, Florida 32801, United States
  • Galderma Investigational Site (Site#8213)
    Ormond Beach, Florida 32174, United States
  • Galderma Investigational Site (Site#8856)
    Ormond Beach, Florida 32174, United States
  • Galderma Investigational Site (Site#8856)
    Ormond Beach, Florida 33174, United States
  • Galderma Investigational Site (Site#8843)
    Sweetwater, Florida 33172, United States
  • Galderma Investigational Site (Site#8764)
    Tampa, Florida 33613, United States
  • Galderma Investigational Site 2 (Site#8816)
    Tampa, Florida 33613, United States
  • Galderma Investigational Site (Site#8839)
    Tampa, Florida 33615, United States
  • Galderma Investigational Site (Site#8739)
    Normal, Illinois 61761, United States
  • Galderma Investigational Site (Site#8142)
    Indianapolis, Indiana 46250, United States
  • Galderma Investigational Site (Site#8532)
    Overland Park, Kansas 66215, United States
  • Galderma Investigational Site (Site#8812)
    Metairie, Louisiana 70005, United States
  • Galderma Investigational Site (Site#8793)
    Towson, Maryland 21204, United States
  • Galderma Investigational Site (Site#8033)
    Clinton Township, Michigan 48038-1137, United States
  • Galderma Investigational Site (Site#8129)
    Fort Gratiot, Michigan 48059, United States
  • Galderma Investigational Site (Site#8849)
    Troy, Michigan 48084, United States
  • Galderma Investigational Site (Site#8876)
    Bridgeton, Missouri 63044, United States
  • Galderma Investigational Site (Site#8847)
    Las Vegas, Nevada 89118, United States
  • Galderma Investigational Site (Site#8848)
    Las Vegas, Nevada 89144, United States
  • Galderma Investigational Site 2 (Site#8864)
    Las Vegas, Nevada 89144, United States
  • Galderma Investigational Site (Site#8420)
    Portsmouth, New Hampshire 03801, United States
  • Galderma Investigational Site (Site#9924)
    Raritan, New Jersey 08869, United States
  • Galderma Investigational Site (Site#8828)
    Kew Gardens, New York 11415, United States
  • Galderma Investigational Site (Site#9919)
    Raleigh, North Carolina 27617, United States
  • Galderma Investigational Site (Site#8795)
    Shelby, North Carolina 28150, United States
  • Galderma Investigational Site (Site#8857)
    Oklahoma City, Oklahoma 73118, United States
  • Galderma Investigational Site (Site#8841)
    Medford, Oregon 97504, United States
  • Galderma Investigational Site (Site#8428)
    Philadelphia, Pennsylvania 19104, United States
  • Galderma Investigational Site (Site#8353)
    Yardley, Pennsylvania 19067, United States
  • Galderma Investigational Site (Site#8777)
    Charleston, South Carolina 29407, United States
  • Galderma Investigational Site (Site#8200)
    Goodlettsville, Tennessee 37072, United States
  • Galderma Investigational Site (Site#8846)
    Austin, Texas 78742, United States
  • Galderma Investigational Site (Site#8855)
    Beaumont, Texas 77702, United States
  • Galderma Investigational Site (Site#8245)
    Dallas, Texas 75231, United States
  • Galderma Investigational Site (Site#8868)
    Houston, Texas 77004, United States
  • Galderma Investigational Site (Site#8817)
    Katy, Texas 77494, United States
  • Galderma Investigational Site (Site#8787)
    Plano, Texas 75093, United States
  • Galderma Investigational Site (Site#8329)
    San Antonio, Texas 78229-3409, United States
  • Galderma Investigational Site (Site#8003)
    Webster, Texas 77598, United States
  • Galderma Investigational Site (Site#8844)
    Orem, Utah 84058, United States
  • Galderma Investigational Site (Site#9935)
    Springville, Utah 84663, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2020 to primary completion in Jul 2023, 40 months.

Results were first posted in Jun 2025, 1 year 10 months after primary completion. A results delay was requested in Apr 2024.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 40 months is above that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2020
First posted
Apr 28, 2020
StartActual
Mar 5, 2020
Primary completionActual
Jul 7, 2023
CompletionActual
Jul 7, 2023
Results delay requested
Apr 24, 2024
Results first posted
Jun 5, 2025
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04365387
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Apr 28, 2020
Start date
Mar 5, 2020
Primary completion
Jul 7, 2023
Completion
Jul 7, 2023
Results posted
Jun 5, 2025
Last update
Jun 1, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nemolizumab

Start the discussion